Exicure (NASDAQ:XCUR) Posts Quarterly Earnings Results, Beats Expectations By $18.14 EPS

Exicure (NASDAQ:XCUR) released its quarterly earnings results on Wednesday. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($18.60) by $18.14, FiscalAI reports.

Exicure Stock Performance

Shares of XCUR traded up $0.02 during mid-day trading on Wednesday, reaching $4.49. The company had a trading volume of 16,841 shares, compared to its average volume of 33,996. The company has a market capitalization of $28.60 million, a price-to-earnings ratio of -1.21 and a beta of 4.13. The firm has a 50-day moving average price of $4.44 and a 200 day moving average price of $4.66. Exicure has a 52 week low of $3.10 and a 52 week high of $14.73.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Exicure in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Exicure to a “hold” rating in a research note on Saturday, January 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.